MiNK Therapeutics, Inc.

MiNK Therapeutics, Inc.

INKT · Nasdaq

MiNK Therapeutics, Inc. (INKT) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for MiNK Therapeutics, Inc. in 2026. The next earnings report is expected on November 13, 2026.

Earnings calendar

Next earnings date

13 Nov 2026

In 85 days

EPS estimate

-0.63

Revenue estimate

0

Past earnings

13 Aug 2026
EPS actual
-0.62 (-3.3%)
estimate -0.60
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
13 May 2026
EPS actual
—
estimate -0.77
Revenue actual
—
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
31 Mar 2026
EPS actual
-0.52 (+23.5%)
estimate -0.68
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
14 Nov 2025
EPS actual
-0.65 (+24.0%)
estimate -0.86
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Latest earnings analysis

MiNK Therapeutics, Inc. missed consensus on EPS in its latest report, with EPS of -$0.62 versus an estimate of -$0.60, while revenue met expectations at $0. In the prior quarter, EPS was ahead of expectations and revenue likewise met estimates.

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
Nasdaq
CEO
Jennifer S. Buell
Employees
23
IPO date
15 Oct 2021
ISIN
US6036932019
Website
minktherapeutics.com

Frequently asked questions

When does MiNK Therapeutics, Inc. (INKT) next report earnings?

MiNK Therapeutics, Inc. (INKT) is scheduled to report earnings on November 13, 2026.

What was MiNK Therapeutics, Inc.'s most recent earnings date?

MiNK Therapeutics, Inc. (INKT) last reported earnings on August 13, 2026.

Where is MiNK Therapeutics, Inc. stock listed?

MiNK Therapeutics, Inc. (INKT) is listed on Nasdaq.